For pharmaceutical companies
Expand your discovery pipeline with precision and scale
Large pipelines don’t guarantee better outcomes. Vipergen gives your discovery teams access to new chemical space, harder-to-drug targets, and higher-quality hits — through proprietary DEL technology that goes beyond conventional screening.
The modern pharma reality
Built for modern drug discovery
Traditional screening approaches fall short when biology gets difficult. Our platform is designed to go beyond those limitations.
Increasingly complex and novel targets
First-in-class programs require access to target classes that conventional methods can’t address. Our in-cell screening extends your reach.
Rising R&D costs and attrition rates
Early-stage decisions define late-stage outcomes. Higher hit quality upfront means fewer costly failures downstream.
Pressure to accelerate without compromising quality
Speed and rigor are not mutually exclusive. Our platform delivers ranked, actionable hits with structural data — fast.
Demand for first-in-class therapies
Accessing unexplored chemical space is critical for differentiated programs. We screen 500M+ drug-like molecules per experiment.
“Incremental improvements are no longer enough. You need new ways to access chemical space and reduce risk early”
90+
pharma & biotech partnerships worldwide
3
proprietary DEL technologies — yR, BTE & cBTE
How it works
Seamless integration into your existing workflows
We act as an extension of your discovery team — delivering high-quality results without disrupting your pipeline or requiring operational overhead.
01
Define the program
We align on target class, biology, and objectives. Whether a single campaign or a multi-target collaboration, we tailor the approach to your pipeline needs.
02
DEL screening at scale
Hundreds of millions of compounds screened per experiment — in vitro via BTE or directly inside living cells via cBTE, depending on target and program requirements.
03
Ranked hits with structural data
Your teams receive prioritized hit lists with structural insight, ready for validation and rapid progression into lead optimization.
Our platform
Technology that unlocks previously inaccessible targets
Three proprietary 2nd and 3rd generation DEL technologies — each addressing a different layer of biological complexity and discovery need.
Library synthesis
YoctoReactor® (yR)
Creates vast small-molecule DELs with a perfect match between DNA barcodes and displayed compounds — the foundation for high-fidelity screening. Enables ultra-high screening capacity in a single experiment.
In vitro screening
Binder Trap Enrichment® (BTE)
A homogeneous in vitro screening technology for rapid, comprehensive DEL screening. Ideal for targets where purified protein is available and in vitro conditions are appropriate.
In-cell screening
Cellular BTE® (cBTE)
The world’s only technology for screening DELs inside a living cell. No purified protein needed. More physiologically relevant results from day one — expanding the target space to previously “undruggable” biology.
Partnership frameworks
You keep everything. Full stop.
We understand the importance of confidentiality, scalability, and strategic alignment. Our frameworks are designed to integrate smoothly while protecting long-term value.
Clear and transparent IP frameworks
Defined ownership of project outcomes and generated data from the outset. No ambiguity in what belongs to whom.
Smooth workflow integration
Efficient onboarding and integration into your existing discovery programs. We adapt to your processes, not the other way around.
Flexible collaboration structures
From single-target fee-for-service campaigns to broad strategic collaborations — tailored to your pipeline scope and timelines.
Confidentiality and operational scalability
Full discretion on program details. Our platform scales to support multi-target, multi-indication programs without added complexity.
Track record
Proven with the world’s leading pharma companies
Vipergen has established partnerships with top-10 pharma companies across the US, EU, and Japan — bringing the same platform to every collaboration, regardless of scale.
90+
Partnerships closed with pharma and biotech companies globally — from early-stage biotechs to top-5 global pharmaceutical companies.
500M+
Drug-like molecules screened per experiment via the YoctoReactor® platform — providing unmatched chemical space coverage in a single run.
#1
The first and only company screening DNA-encoded libraries inside living cells — enabling a level of biological relevance no other platform can match.
When to work with us
The right partner when standard approaches fall short
Whether supporting a targeted campaign or a pipeline-wide collaboration, Vipergen integrates where conventional screening hits its limits.
Target validation for novel biology
Generate hit data against previously untested targets before committing significant internal resources to a new program.
Hit identification for difficult targets
GPCRs, ion channels, PPIs, and other challenging target classes are where in-cell DEL screening most clearly outperforms conventional in vitro methods.
Expanding chemical space coverage
Access chemotypes and binding modes beyond what internal compound collections can offer — increasing the probability of finding first-in-class leads.
Reducing late-stage attrition
Physiologically relevant screening from day one means fewer surprises downstream. Better early data leads to better development decisions.
Accelerating hit-to-lead progression
Ranked hit lists with structural data allow your medicinal chemistry teams to move directly to SAR — bypassing weeks of weak-signal triage.
Augmenting internal screening capabilities
Complement your HTS and in-house DEL capabilities with an external platform optimized for the targets your current setup can’t address.